$206.78

+1.08 (+0.53%)

Weekly Expected Move ±3.7%

$198 $206 $214 $222 $230

NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 35 · $13.4B mcap · 62M float · 1.39% daily turnover · Short 50% of daily vol

Credit Risk of going bust: lower than 57% of companies Debt: 24.7% of company value Bonds: $459.8M held by 158 funds, 99 bp over Treasuries → details ▾

If the stock fell to about $5.81 (down 97%), Jazz Pharmaceuticals plc would be worth roughly what it owes.
Total debt $4.41B against a stock market value of $13.42B.
Distance to default 5.85 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.68B (short-term plus half of long-term), stock volatility 36.3%; Altman Z'' 2.72. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest Supply Chain

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$4.3B +4.9% ▲

5Y CAGR: +12.5%

Gross Profit

$3.8B +3.9% ▲

5Y CAGR: +11.2%

Operating Income

$224M -68.7% ▼

5Y CAGR: -9.9%

Net Income

-$356M -163.6% ▼

EPS (Diluted)

$-5.84 -167.5% ▼

EBITDA

$108M -92.9% ▼

5Y CAGR: -36.4%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$3.1B	$3.7B	$3.8B	$4.1B	$4.3B
YoY Growth	+30.9%	+18.3%	+4.8%	+6.1%	+4.9%
Cost of Revenue	$441M	$541M	$436M	$446M	$503M
Gross Profit	$2.7B	$3.1B	$3.4B	$3.6B	$3.8B
Gross Margin	85.8%	85.2%	88.6%	89.0%	88.2%
R&D Expenses	$506M	$590M	$850M	$884M	$783M
SG&A Expenses	$1.5B	$1.4B	$1.3B	$1.4B	$1.8B
Operating Expenses	$2.5B	$3.2B	$2.8B	$2.9B	$3.5B
Operating Income	$170M	-$66M	$579M	$717M	$224M
Operating Margin	5.5%	-1.8%	15.1%	17.6%	5.3%
Interest Expense	$279M	$288M	$289M	$238M	$195M
Income Before Tax	-$114M	-$383M	$295M	$469M	-$629M
Tax Expense	$216M	-$159M	-$120M	-$91M	-$272M
Net Income	-$329M	-$224M	$415M	$560M	-$356M
Net Margin	-10.6%	-6.1%	10.8%	13.8%	-8.3%
EPS (Diluted)	$-5.51	$-3.58	$6.10	$8.65	$-5.84
EBITDA	$1.0B	$1.5B	$1.4B	$1.5B	$108M
Shares Outstanding	60M	63M	72M	66M	61M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$1.1B	$1.1B	$898M	$1.0B	$1.1B	$1.2B	$1.1B	$1.2B
Cost of Revenue	$112M	$129M	$105M	$116M	$258M	$25M	$306M	$116M
Gross Profit	$943M	$959M	$793M	$929M	$868M	$1.2B	$762M	$1.1B
Gross Margin	89.4%	88.2%	88.3%	88.9%	77.1%	97.9%	71.3%	90.4%
R&D Expenses	$200M	$240M	$181M	$190M	$241M	$171M	$134M	$208M
SG&A Expenses	$326M	$369M	$514M	$358M	$531M	$406M	$353M	$389M
Operating Expenses	$683M	$769M	$849M	$1.6B	$811M	$264M	$549M	$844M
Operating Income	$260M	$191M	-$56M	-$686M	$58M	$909M	$214M	$248M
Operating Margin	24.7%	17.5%	-6.2%	-65.6%	5.1%	75.9%	20.0%	20.5%
Interest Expense	$59M	$51M	$54M	$47M	$49M	$45M	$63M	$37M
Income Before Tax	$201M	$133M	-$110M	-$736M	$9M	$208M	$299M	$211M
Tax Expense	-$15M	-$58M	-$18M	-$17M	-$242M	$5M	$6M	$18M
Net Income	$215M	$191M	-$93M	-$718M	$251M	$203M	$293M	$193M
Net Margin	20.4%	17.6%	-10.3%	-68.7%	22.3%	17.0%	27.4%	16.0%
EPS (Diluted)	$3.42	$3.11	$-1.52	$-11.74	$4.08	$3.34	$4.43	$2.78
EBITDA	$425M	$397M	$139M	-$514M	$236M	$279M	$544M	$427M
Shares Outstanding	63M	62M	61M	61M	62M	61M	66M	69M

JAZZ NASDAQ